Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Titan's assets are worth 5 million!
there is this feeling of vomiting!
They are giving us a tip perhaps to avoid responsibility!
in CBIO now GYRE worked well for me, looks similar! ...I entered low, a bit like Titan is now.
How disgusting!
Well, tomorrow is another day!
I don't know how or if it's worth it, but if someone organizes something for the total bullshit carried out by Vance, McNally, Cataford & Company, count me in!
I hold!
We are the first to be fleeced by MDT, who wanted Vance in Titan? fuck off
Here's another one that didn't age well.. LOL. They were all kinds of intelligent people on this board.. until one day they're no longer intelligent.
"Patiently awaiting the ride back up. Executives holding and so am I."
You will probably have 90% less shares.. not that they're worth a shit right now anyway.. but yes, definitely vote no.. even so they'll still find a way to screw shareholders and vote us right out.. what do you think they've been working on all this time?? Enos?? LOL
Hey, where is Boom Boom Frankenstein today with his happy patent messages? You know, it's all in the patents
HERE IS WHAT WILL HAPPEN TO TITAN SHARES:
So what do you think this does to our shares? How are they affected specifically?
You can now say Titan has been scooped.
“Reverse takeover of Titan”
Looks like the carcass has been devoured.
How about those patents for Enos?? Looks like Enos just got retired. Boom! Prepare to get screwed again
https://worldwide.espacenet.com/patent/search/family/087930037/publication/WO2024042472A1?q=pn%3DWO2024042472A1
Publication WO2024042472A1·2024-02-29
visible recently not since the 29th
it's the same patent
For Enos 2, Covidien reigns in the world and Titan reigns in the USA!?!?
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11918185
Who will this be for?
Will we get anything?
Is it possible that everything can be kept hidden? With all the lies they wrote in the SEC files they risk liability!
We can say that they all work for MDT!
Everyone in MDT is ethical, I hope they stop doing gay with our ass!
We have a Load of Patents and we need cash now .........call MD TRONIC 877cashnow.
BOOOOOOM!
It’s All in the patents!
HERE IT IS!
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240065538
That's beautiful!
What do you think about it?
Did you imagine it?
HERE IT IS!
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240065538
That's beautiful!
What do you think about it?
Did you imagine it?
looks like a direct competitor of vicarius!
Anyone who has invested in RBOT will be happy! LOL
What they like comes from Titan's patents or am I wrong?
https://onlinelibrary.wiley.com/doi/epdf/10.1002/rcs.2577
https://www.01net.it/virtual-incision-receives-fda-authorization-for-the-mira-surgical-system-as-the-first-miniaturized-robotic-assisted-surgery-device/
FDA for Virtual Incision Mira RAS
Thoughts???
agree with you on un-American by being silenced. However the company, Titan Medical is the one that ruined this board and all of its investors. There's no reason to look any further. And anyone that still talking about scooping as if this company has any positive future at all, was likely never an investor but yet another imposter posing as an investor for the nefarious Acts. It seems nowadays that evil is the only thing that is allowed to stand
They tried some other stocks….those tanked too….
But they are VERY smart!
Just ask them
Truth. I wonder how the big scoopers doing. Does it's still post here? What about Big T? Or Big Kahuna? And many of the other names long forgotten.. likely hiding in shame or stroke from the Los and shame
It’s all in the patents
15 Titan investors that had open-ended plane tix for Vegas have since died of old age. Yep
#RIP
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240058086
I have about 77,700 shares and they will remain there until the end.
I guess I'll keep reading helpful and uplifting comments like a finger in the ass!
One thing I know, the one who has to lose here is no longer me!
The probability of earning here is much higher than losing!
Something's cooking and MDT, ISRG and J&J are at the table!
We are so small that their crumbs can feed us!!!!
Martha wants this cheap….
He doesn’t want another Mazor…
Buyout coming!
Exciting times
Should we still be averaging down? I gotta think a buy out is very soon now since we've been talking about it of 12+years.. I see the same turds are still here posting. Don't seem like any scooping is being done except by a bride frankestin. Nice to see all the support for titan by one single person. He probably knows something that nobody else does. God bless all. See you in Vegas.
What is that? Some sort of carpet cleaning machine? Or, is it portfolio cleaning machine?
Foot Pedal Apparatus For Use With A Workstation Controlling A Robotic Surgery System
DOCUMENT ID
US 11907001 B2
DATE PUBLISHED
2024-02-20
ASSIGNEE INFORMATION
NAME
Titan Medical Inc.
COVIDIEN isn't interested in pedals?
However, they seem to be interested in the method for capturing images. All about ENOS1.
Perhaps the one relating to image capture is a patent exclusive to MDT and that TITAN can use for the single door.
how much patience!
When will the FDA approve HUGO? Maybe afterwards they will be more humane towards us? mmm I doubt it but maybe I'm wrong
COVIDIEN patents ENOS2!
if they had sold enos 2 for 8 million and that's it without anything else then they are criminals, if so it's a total scam.
I reinvested the gain made in TMDI to see the marketing of ENOS 1, as widely supported by them and not for ENOS 2!
If they spent everything on ENOS 2, how could they have sold it for only 8 million?
MDT has always purchased companies with which it has entered into partnerships.
Why is there even a partnership agreement with ISRG? how to frame it?
Then there is a licensing agreement with J&J, perhaps free of charge since the anos is ours!
https://www.medtechdive.com/news/jj-fda-ide-ottava-surgical-robot/699013/
https://patents.justia.com/patent/11751961
Systems, Methods, And Apparatuses For Capturing Images During A Medical Procedure
PATENT NUMBER
11751961
DOCUMENT ID
US 11751961 B2
DATE PUBLISHED
2023-09-12
INVENTOR INFORMATION
NAME
CITY
STATE
ZIP CODE
COUNTRY
Genova; Perry A. Sankholkar; Sachin A. Highlands Ranch Pflaumer; Hans Christian Apex Laakso; Aki Hannu Einari Raleigh Katz; Allan
Farmingdale Espinosa; Alejandro Miramar Ampuero; Eduardo A. Miramar
ASSIGNEE INFORMATION
NAME
COVIDIEN LP
Hey Lupin 777
When do you think they will start producing enos 2? And who do you think will sell them?
tell us something
It’s all in the patents
This is the second time you've made me boom on this topic... but you don't say anything significant!
Doesn't it shock you to see that Enos 2 is being patented?
Me yes!
In your opinion, Covidien patents everything and Titan can commercialize the single door use that they are patenting?
IMO
ISRG must avoid monopoly!
J&J wants in and has entered into a licensing agreement with Titan
So we are at. 7 cent!
https://seekingalpha.com/article/4653309-intuitive-surgical-monopoly-days-may-be-over
and then?
what do you think?
I thought the use of single port technology was reserved for Titan.
How should it be interpreted?
Under the Medtronic APLA, while Titan sold certain of its IP to Medtronic, Titan received a limited license back to the Acquired Rights consistent with the rights retained by Titan for the exclusively licensed IP under the Medtronic Agreements to commercialize the licensed technologies in single access RAS, including with the Enos System and enhancements thereof, should the Company choose to do so. Under the Medtronic APLA Titan may assign its IP rights thereunder in connection with the sale of all or substantially all of the assets of Titan or in connection with a "change of control" (as such term is defined therein). Titan retains ownership of the Licensed IP, along with the associated rights including the right to continue to develop and commercialize the technologies covered by the Licensed IP and the right to further license the Licensed IP to other third parties. Under the Intuitive License Agreement, Titan retains ownership of the licensed IP, along with the associated rights including the right to continue to develop and commercialize the technologies covered by the licensed IP and the right to license the IP to other third parties.
How good they are….. how human they are!
https://news.medtronic.com/2023-03-13-Medtronic-named-one-of-Worlds-Most-Ethical-Companies
https://www.cambridge-design.com/news/cdp-advances-surgical-robotic-technology/
Under the terms of the Agreement, Titan has (i) sold to Medtronic the patents previously exclusively licensed by Titan to Medtronic under a license agreement dated June 3, 2020 and under a development and license agreement dated June 3, 2020 (“Acquired Rights”), and (ii) granted Medtronic a non-exclusive license to certain other Titan intellectual property, excluding the Acquired Rights (“Licensed IP”). Medtronic has granted Titan a limited non-exclusive license back to the Acquired Rights and Titan retains ownership of the Licensed IP, along with the associated rights including the right to continue to develop and commercialize the technologies covered by the Licensed IP and the right to further license the Licensed IP to other third parties.
Why is Enos 2 patented by Covidien?
Do they fun with our Anos?
7 cent!
BUT Gary (G because he play with our enos) Does Not Sell… mmmm
https://www.ldmicro.com/profile/tmd.to/insiders
How ethical they are!
thelma was a hottie and the next door neighbor wasnt bad either but thelma takes the cake,God bless all
Who’s hotter? Weezy or Florida Evans?
Followers
|
493
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
140432
|
Created
|
10/18/10
|
Type
|
Free
|
Moderators Honeycomb777 SPORT19 livendi |
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |